Oxford Biomedica (OXB.L) — insider trading
A leader in the viral vector manufacturing sector, providing essential development and production services for advanced cell and gene therapy treatments.
SEC Form 4 insider transactions are not available for Oxford Biomedica (OXB.L) — this comes from a US regulatory filing with no equivalent in our UK sources.
We ingest insider filings from SEC EDGAR, which covers issuers subject to US reporting requirements. See the full company profile for the data we do hold on this company.
More on Oxford Biomedica: company profile · SEC filings · congressional trading · similar companies.
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR.